• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型羧基喹诺酮类药物氧氟沙星的磁盘药敏试验

Disk susceptibility of ofloxacin, a new carboxyquinolone.

作者信息

Mandell W, Neu H C

出版信息

J Clin Microbiol. 1985 Nov;22(5):786-8. doi: 10.1128/jcm.22.5.786-788.1985.

DOI:10.1128/jcm.22.5.786-788.1985
PMID:3863833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC268527/
Abstract

Ofloxacin, a fluorinated carboxyquinolone, was tested against 485 clinical isolates, and the MICs and disk inhibitory zones were correlated. A critical zone of greater than or equal to 19 mm and an MIC of less than or equal to 2 micrograms/ml indicate susceptibility. An MIC of 4 micrograms/ml and a zone size of 16 to 18 mm is intermediate, and an MIC of greater than or equal to 8 micrograms/ml with a zone size of less than 15 mm indicates resistance. Alternatively, organisms inhibited by an MIC of less than or equal to 4 micrograms/ml with a critical zone diameter of greater than or equal to 15 mm could be considered susceptible. By either of these criteria, major errors in judging susceptibility or resistance are less than 1%.

摘要

氧氟沙星,一种氟化羧基喹诺酮类药物,对485株临床分离菌进行了测试,并对其最低抑菌浓度(MIC)和纸片抑菌圈进行了相关性分析。临界抑菌圈直径大于或等于19毫米且MIC小于或等于2微克/毫升表明敏感。MIC为4微克/毫升且抑菌圈大小为16至18毫米为中介,MIC大于或等于8微克/毫升且抑菌圈大小小于15毫米表明耐药。另外,临界抑菌圈直径大于或等于15毫米且MIC小于或等于4微克/毫升时被抑制的菌株可被视为敏感。按照这两种标准中的任何一种,判断敏感或耐药的主要误差均小于1%。

相似文献

1
Disk susceptibility of ofloxacin, a new carboxyquinolone.新型羧基喹诺酮类药物氧氟沙星的磁盘药敏试验
J Clin Microbiol. 1985 Nov;22(5):786-8. doi: 10.1128/jcm.22.5.786-788.1985.
2
Proposed disk diffusion susceptibility criteria for ofloxacin.氧氟沙星的纸片扩散法药敏试验推荐标准。
J Clin Microbiol. 1985 Aug;22(2):310-1. doi: 10.1128/jcm.22.2.310-311.1985.
3
CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
Diagn Microbiol Infect Dis. 1987 Mar;6(3):185-92. doi: 10.1016/0732-8893(87)90011-3.
4
Interpretive criteria for the agar diffusion susceptibility test with ofloxacin.氧氟沙星琼脂扩散药敏试验的解释标准。
Drugs. 1987;34 Suppl 1:14-9. doi: 10.2165/00003495-198700341-00004.
5
[Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].[对美国国家临床实验室标准委员会(NCCLS)指南及世界卫生组织(WHO)标准中妥舒沙星和洛美沙星药敏试验拟定标准的评估]
Rinsho Byori. 1992 Jan;40(1):73-80.
6
[Criteria for the interpretation of sensitivity testing of ofloxacin with the agar diffusion test].[氧氟沙星琼脂扩散试验敏感性检测结果的解读标准]
Infection. 1986;14 Suppl 1:S16-9. doi: 10.1007/BF01645192.
7
Cefoperazone: regression analysis, disk content, and disk susceptibility testing considerations.头孢哌酮:回归分析、纸片含量及纸片药敏试验注意事项。
Antimicrob Agents Chemother. 1982 Sep;22(3):493-8. doi: 10.1128/AAC.22.3.493.
8
In vitro antimicrobial activity and susceptibility testing of ofloxacin. Current status.氧氟沙星的体外抗菌活性及药敏试验。现状。
Am J Med. 1989 Dec 29;87(6C):10S-13S.
9
[Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test].[估计头孢甲肟有效给药剂量的临床实验室方法。对最小抑菌浓度(MICS)和头孢甲肟纸片药敏试验的观察]
Jpn J Antibiot. 1984 May;37(5):791-801.
10
[Multicenter study of ofloxacin activity on bacteria isolated from a hospital environment].[氧氟沙星对医院环境分离细菌活性的多中心研究] (注:原文中多了一个of,正确表述应该是Multicenter study of ofloxacin activity on bacteria isolated from a hospital environment )
Pathol Biol (Paris). 1986 May;34(5):390-8.

引用本文的文献

1
Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.每日一次芦氟沙星与每日两次氧氟沙星治疗复杂性膀胱炎和上尿路感染。意大利多中心泌尿道感染芦氟沙星研究组
Infection. 1993 Mar-Apr;21(2):106-11. doi: 10.1007/BF01710743.
2
Fluoroquinolone antimicrobial agents.氟喹诺酮类抗菌剂。
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
3
Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria.氧氟沙星微量稀释法和纸片扩散法药敏试验的质量控制参数以及纸片扩散法解释标准的确认。
J Clin Microbiol. 1989 Jan;27(1):49-52. doi: 10.1128/jcm.27.1.49-52.1989.
4
Pharmacokinetics of quinolones: newer aspects.
Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):267-74. doi: 10.1007/BF01967000.

本文引用的文献

1
In vitro and in vivo activity of DL-8280, a new oxazine derivative.新型恶嗪衍生物DL-8280的体外和体内活性
Antimicrob Agents Chemother. 1982 Oct;22(4):548-53. doi: 10.1128/AAC.22.4.548.
2
In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.环丙沙星与其他新型含氟哌嗪基取代喹啉衍生物的体外活性比较。
Antimicrob Agents Chemother. 1984 Apr;25(4):518-21. doi: 10.1128/AAC.25.4.518.
3
The pharmacokinetics and tissue penetration of ofloxacin.氧氟沙星的药代动力学和组织穿透性。 (注:原文中多了一个of,正确表述应该是The pharmacokinetics and tissue penetration of ofloxacin )
J Antimicrob Chemother. 1984 Dec;14(6):647-52. doi: 10.1093/jac/14.6.647.
4
Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.氧氟沙星(HOE 280 DL 8280)与萘啶酸类似物的体外和体内抗菌活性比较。
Eur J Clin Microbiol. 1983 Dec;2(6):548-53. doi: 10.1007/BF02016563.
5
Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.厌氧菌药敏试验:统计学与临床考量
J Infect Dis. 1974 Dec;130(6):588-94. doi: 10.1093/infdis/130.6.588.